These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27192330)

  • 1. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone.
    Herbeck DM; Jeter KE; Cousins SJ; Abdelmaksoud R; Crèvecoeur-MacPhail D
    J Addict Dis; 2016; 35(4):305-314. PubMed ID: 27192330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A demonstration project implementing extended-release naltrexone in Los Angeles County.
    Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
    Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
    Springer SA; Brown SE; Di Paola A; Altice FL
    Drug Alcohol Depend; 2015 Dec; 157():158-65. PubMed ID: 26560326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
    Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
    Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
    Crits-Christoph P; Markell HM; Gibbons MB; Gallop R; Lundy C; Stringer M; Gastfriend DR
    J Subst Abuse Treat; 2016 Nov; 70():50-57. PubMed ID: 27692188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release intramuscular naltrexone.
    Swainston Harrison T; Plosker GL; Keam SJ
    Drugs; 2006; 66(13):1741-51. PubMed ID: 16978037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-acting naltrexone--a new way out of opiate addiction?].
    Stavseth LS; Kunøe N; Tanum L
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
    [No Abstract]   [Full Text] [Related]  

  • 18. The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
    Cousins SJ; Crèvecoeur-MacPhail D; Kim T; Rawson RA
    J Subst Abuse Treat; 2018 Feb; 85():78-83. PubMed ID: 28291571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.